Medical Device Outsourcing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The medical device outsourcing market size was valued at USD 131.59 billion in 2025 and is estimated to grow from USD 148.64 billion in 2026 to reach USD 273.38 billion by 2031, at a CAGR of 12.96% during the forecast period (2026-2031). This report is Segmented by Service Type (Product Design and Development Services, Product Testing and Sterilization Services, and More), Device Class (Class I Medical Devices, and More), Device Type (Consumables, Capital Equipment, and More), Application (Cardiovascular, Orthopedic, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Medical Device Outsourcing Market Trends and Insights

Rising OEM Focus on Core Competencies and Cost Optimization

Medical device OEMs are concentrating on product design, intellectual property, and commercialization while outsourcing capital-intensive production tasks to specialized partners. This shift reduces the burden of managing cleanroom qualifications, sterilizations, and process validations in-house. The medical device outsourcing market benefits as OEMs treat these activities as variable operating costs rather than fixed assets. With broader therapy portfolios, qualification demands, documentation, and complexity increase, making outsourcing a strategic choice. Major platforms are integrating manufacturing, sterilization, and quality support, enabling OEMs to lower asset intensity and enhance flexibility without losing commercial focus.

Faster Time to Market for Complex Medical Devices

Speed is a critical factor for OEMs launching minimally invasive systems, connected platforms, and combination products in regulated categories. The medical device outsourcing market gains as established partners streamline documentation, verification, and pre-launch processes. Pre-validated templates and experienced quality teams reduce delays, especially for devices requiring extensive biocompatibility and sterile processing. Outsourcing partners with cleanroom capacities enable faster commercialization by eliminating the need for OEMs to build and validate new infrastructure. Partnerships like Jabil's 2025 collaboration with HSE AG highlight the focus on accelerating prototype-to-market transitions while enhancing supply chain resilience. The market thus delivers both production capacity and commercially critical time.

Quality Liability and Recall Risk Across Outsourced Supply Chains

Legal manufacturers remain responsible for device quality, even when production involves multiple external partners. OEMs cannot fully transfer regulatory obligations through contracts, making quality oversight a critical challenge in the medical device outsourcing market. The complexity increases for devices requiring specialized suppliers for coatings, machining, sterilization, and assembly across various locations. Europe’s expanded supply chain liability adds pressure on indemnification, supplier controls, and documentation, raising costs for audits, quality agreements, and corrective actions. While the market grows, quality accountability drives cautious outsourcing decisions in sensitive categories.

Other drivers and restraints analyzed in the detailed report include:

• Growing Need for Scalable Regulated Manufacturing Capacity
• Rising Outsourcing of Design, Development, and Validation Work
• High Switching Costs Due to Validation, Tooling, and Requalification

Segment Analysis

In 2025, contract manufacturing accounted for 55.13% of the revenue, maintaining its leading role in the medical device outsourcing market. This dominance reflects OEMs' preference for outsourcing precision machining, cleanroom assembly, sterilization integration, and subsystem qualification, which require specialized assets and stringent quality systems. Production remains the primary outsourcing choice due to its significant capital requirements and cost flexibility, anchoring revenue even as other functions gain importance.

Regulatory consulting services are the fastest-growing segment, driven by increasing compliance complexities that OEMs find challenging to manage internally. Other services, including product testing, sterilization, design and development, upgrades, maintenance, and logistics, are also expanding. Early collaboration in product design reduces design transfer issues, while logistics and aftermarket support are increasingly integrated into broader service contracts, narrowing the gap between manufacturing and service bundles.

Class III devices are projected to grow at a 14.55% CAGR through 2031, outpacing the overall market average. This growth is driven by increased outsourcing demand for implantable and clinically complex devices, requiring expertise in sterile processing and biocompatibility. The shift highlights that outsourcing is increasingly capability-driven, especially for high-risk, complex products, positioning Class III programs as a key growth area for specialized partners.

Class II devices remained the largest revenue segment in 2025, supported by cardiovascular, orthopedic, and diagnostic programs. Class I devices also contribute significantly, particularly in disposables and consumables, where speed and consistency are prioritized. The market shows a clear distinction between volume-driven outsourcing in Class I and II products and capability-driven outsourcing in Class III. Integer Holdings has invested over USD 700 million in acquisitions since 2025, focusing on cardiovascular systems and neuromodulation capabilities, aligning with the industry's shift toward complex platforms.

Complete Report Scope:

• By Service Type
  • Product Design And Development Services
  • Product Testing And Sterilization Services
  • Regulatory Consulting Services
  • Contract Manufacturing Services
  • Product Upgrade Services
  • Product Maintenance Services
  • Logistics And Aftermarket Services
• By Device Class
  • Class I Medical Devices
  • Class II Medical Devices
  • Class III Medical Devices
• By Device Type
  • Consumables
  • Capital Equipment
  • Implantable Devices
  • In Vitro Diagnostics Devices
  • Wearable Medical Devices
• By Application
  • Cardiovascular
  • Orthopedic
  • Dental
  • Respiratory
  • Drug Delivery
  • Diabetes Care
  • Ophthalmic
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America accounted for 39.56% of the medical device outsourcing market, maintaining its leading regional position. The region benefits from a strong OEM base, established CDMO networks, and alignment with FDA-regulated supply chains. Providers with expertise in 510(k) and PMA-related manufacturing strengthen the ecosystem by supporting documented transfer and scale-up processes. Nearshoring is expanding the region's influence into nearby hubs like Mexico and Costa Rica.

Asia-Pacific is the fastest-growing region in the medical device outsourcing market, with a projected 15.12% CAGR through 2031. Growth is driven by expanding healthcare infrastructure, cost-efficient production, and favorable policies attracting global outsourcing programs. China remains the largest manufacturing base due to its scale and integrated supply chains, but geopolitical uncertainties and tariffs are prompting OEMs to diversify into countries like Malaysia, Thailand, Singapore, and India.

Europe remains a key production base, led by Germany, Ireland, and the UK in cardiovascular, orthopedic, ophthalmic, and IVD programs. Ireland excels in catheter manufacturing, cleanroom assembly, and precision polymer processing. The European Commission’s 2025 proposal to simplify EU MDR and IVDR frameworks and the 2026 regulation on notified body requirements are expected to ease certification bottlenecks, enabling faster outsourcing growth. The Middle East, Africa, and South America hold smaller shares but are gaining strategic importance as OEMs seek diversified manufacturing and resilient supply chains.

List of Companies Covered in this Report:

• Benchmark Electronics, Inc.
• Celestica
• Charles River
• Flex
• FUJIFILM
• Gerresheimer
• Integer Holdings
• Jabil
• Minnetronix Medical, Inc.
• Nipro
• Nordson
• Phillips-Medisize, LLC
• Plexus Corp.
• Repligen
• Sanmina Corporation
• TE Connectivity Ltd.
• Trelleborg AB
• Viant Medical, Inc.
• West Pharmaceutical Services
• WuXi AppTec Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support